{"product_id":"sciencegroup-swot-analysis","title":"Science Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eScience Group stands at the intersection of advanced diagnostics and global healthcare services, with strong tech capabilities and client relationships but facing regulatory complexity and margin pressure; uncover strategic opportunities and risks with our full SWOT analysis. Purchase the complete report for a professionally formatted, editable Word and Excel package—designed to support investment decisions, strategic planning, and confident stakeholder presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExceptional Financial Resilience and Record Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScience Group closed 2025 with record adjusted operating profit and strong cash conversion, showing resilience through volatile macro and political conditions.\u003c\/p\u003e\n\u003cp\u003eHigh margins persisted across its consulting and specialist engineering units, underpinning sustained profitability and balance-sheet strength.\u003c\/p\u003e\n\u003cp\u003eIn H1 2025 the group reported profit before tax of £32.2m, which included a one-off £24.0m gain from its Ricardo plc investment, materially lifting results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Balance Sheet and Strong Liquidity Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group closed 2025 with net funds of £61.2 million and gross cash of £72.6 million as of 31 December 2025, giving a very strong liquidity buffer. A recently renewed, undrawn £30 million revolving credit facility further supports short‑term flexibility and risk management. This balance sheet strength funds organic R\u0026amp;D and operations and enables quick execution of acquisitions or strategic investments when opportunities arise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Turnaround and Growth in Systems Businesses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Systems division, led by Critical Maritime Systems \u0026amp; Support (CMS2), delivered a strong turnaround after the 2023 TP Group acquisition, with H1 2025 revenue up 52% to £16.6m, driven by higher defense spend and renewed submarine program work.\u003c\/p\u003e\n\u003cp\u003eThis surge helped offset weaker performance in other service divisions, improving group revenue mix and margin stability through greater exposure to long-term defense contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Diversification Across Key Global Sectors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScience Group’s presence in medical, consumer, industrial, and defense reduces single-market exposure, with revenue across divisions keeping volatility low—medical, consumer, industrial, and defense contributed 34%, 28%, 22%, and 16% of 2024 revenue respectively.\u003c\/p\u003e\n\u003cp\u003eThe multi-divisional model taps deep technical expertise to serve clients in 100+ countries, enabling cross-selling and higher-margin projects; adjusted operating margin was 14.2% in 2024.\u003c\/p\u003e\n\u003cp\u003eThe Medical sector’s recovery in H2 2025 drove a sequential revenue uplift of 9% and helped stabilise group EBITDA, showing diversification’s cushioning effect.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue mix: Medical 34%, Consumer 28%, Industrial 22%, Defense 16%\u003c\/li\u003e\n\u003cli\u003eClients in 100+ countries; adjusted operating margin 14.2% (2024)\u003c\/li\u003e\n\u003cli\u003eMedical +9% revenue sequential in H2 2025; supported group EBITDA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisciplined Capital Allocation and Shareholder Value Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe group keeps a tight capital-allocation discipline, returning £14.3m to shareholders in 2025—£10.7m via buy-backs—and maintaining a regular dividend policy to boost shareholder value.\u003c\/p\u003e\n\u003cp\u003eManagement uses earnings per share (EPS) as the chief performance metric, so deals like the profitable Ricardo investment are pursued only when they clearly lift EPS and investor returns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 returns: £14.3m total, £10.7m buy-backs\u003c\/li\u003e\n\u003cli\u003eConsistent dividend payouts alongside buy-backs\u003c\/li\u003e\n\u003cli\u003eEPS-driven decisions align M\u0026amp;A with shareholder value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience Group posts record profits, £61.2m net funds and £14.3m returned to shareholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScience Group posted record adjusted operating profit in 2025, strong cash conversion, and net funds of £61.2m with £72.6m gross cash and an undrawn £30m RCF; H1 2025 PBT £32.2m (incl. £24.0m Ricardo gain). Diversified revenue (2024: Medical 34%, Consumer 28%, Industrial 22%, Defense 16%), adjusted operating margin 14.2% (2024), returned £14.3m to shareholders in 2025 (£10.7m buy-backs).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet funds (Dec 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e£61.2m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross cash\u003c\/td\u003e\n\u003ctd\u003e£72.6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndrawn RCF\u003c\/td\u003e\n\u003ctd\u003e£30.0m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 PBT\u003c\/td\u003e\n\u003ctd\u003e£32.2m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRicardo gain\u003c\/td\u003e\n\u003ctd\u003e£24.0m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. operating margin (2024)\u003c\/td\u003e\n\u003ctd\u003e14.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue mix\u003c\/td\u003e\n\u003ctd\u003eMed 34% \/ Cons 28% \/ Ind 22% \/ Def 16%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 shareholder returns\u003c\/td\u003e\n\u003ctd\u003e£14.3m (£10.7m buy-backs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Science Group, outlining its core strengths, operational weaknesses, market opportunities, and external threats shaping strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a clear SWOT snapshot tailored to the Science Group for rapid strategic alignment and concise stakeholder updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Volatility Linked to Project-Based Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant share of science group revenue in fy from large project-based consultancy contracts creating cashflow swings when major projects end.\u003e\n\u003cpwhen flagship projects in medical and industrial closed across q1 quarterly revenue dropped yoy affected segments showing sensitivity to project timing.\u003e\n\u003cpif new engagements lag more than one quarter the company risks operating-margin pressure backlog fell from dec to mar underscoring this exposure.\u003e\n\u003c\/pif\u003e\u003c\/pwhen\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Macroeconomic Headwinds in Professional Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Professional Services division is highly sensitive to macroeconomic headwinds, showing a 9.1% revenue decline in H1 2025 as clients in energy and pharmaceuticals delayed R\u0026amp;D and advisory projects, trimming revenue by roughly $14–18m versus H1 2024. This cyclical exposure reduced utilization rates by ~4 percentage points and pressured EBITDA margins through higher fixed-cost absorption. Management must actively adjust staffing and pricing to protect margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Decision-Making and Ownership Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of early 2025 the top five shareholders of Science Group hold \u0026gt;55% of shares, giving strategic stability but concentrating decision-making and control.\u003c\/p\u003e\n\u003cp\u003eThat concentration can raise governance concerns for institutional investors seeking independent oversight and may depress governance scores versus peers with dispersed ownership.\u003c\/p\u003e\n\u003cp\u003eLimited shareholder diversity could reduce strategic input variety, risking groupthink on investments and M\u0026amp;A choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Risks of Complex Specialist Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe group depends on acquisitive growth—TP Group (acquired 2021) and Frontier Smart Technologies (2023) make up ~18% of pro-forma FY2024 revenue, raising integration stakes.\u003c\/p\u003e\n\u003cp\u003eIntegrating niche engineering and tech stacks risks operational slips, with 37% of PE roll-ups failing to meet synergy targets within 24 months.\u003c\/p\u003e\n\u003cp\u003eFailures could divert senior management time, dilute EBITDA margin (TP\/Frontier contributed 2.1ppt lower margin in FY2024), and disrupt client delivery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% pro-forma FY2024 revenue from recent specialist buys\u003c\/li\u003e\n\u003cli\u003e37% of roll-ups miss 24‑month synergy targets\u003c\/li\u003e\n\u003cli\u003e2.1ppt margin drag from TP\/Frontier in FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Valuation Disconnect and Low Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite reported revenue growth of 18% and adjusted EBITDA margin of 22% in FY2024, the board repeatedly flags a valuation gap: Science Group’s shares traded at a median P\/E of ~12x in 2024 versus 18x for UK tech\/consult peers, reflecting low average daily volume of ~120k shares on AIM.\u003c\/p\u003e\n\u003cp\u003eThis low liquidity has made equity-funded acquisitions costly, widening the premium required for sellers and limiting M\u0026amp;A flexibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue +18%\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA margin 22%\u003c\/li\u003e\n\u003cli\u003eMedian P\/E ~12x vs peers ~18x\u003c\/li\u003e\n\u003cli\u003eAvg daily volume ~120k shares on AIM\u003c\/li\u003e\n\u003cli\u003eEquity currency less attractive for M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProject revenue slump, backlog down and concentrated ownership squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cprevenue concentration in project-based consultancy fy2024 causes quarterly cashflow swings segment revenue fell yoy after project closures. backlog down and h1 services trimming utilization top-five shareholders\u003e55% concentrates control; recent acquisitions =18% pro‑forma revenue with a 2.1ppt margin drag. \u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProject revenue\u003c\/td\u003e\n\u003ctd\u003e42% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment drop\u003c\/td\u003e\n\u003ctd\u003e~18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBacklog change\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 services\u003c\/td\u003e\n\u003ctd\u003e-9.1% (~$14–18m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop5 ownership\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisitions\u003c\/td\u003e\n\u003ctd\u003e18% pro‑forma; -2.1ppt margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/prevenue\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eScience Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; once purchased, the complete, editable version is unlocked. You’re viewing a live excerpt of the real file, structured and ready to use immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752253632889,"sku":"sciencegroup-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sciencegroup-swot-analysis.png?v=1772238651","url":"https:\/\/matrixbcg.com\/products\/sciencegroup-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}